论文部分内容阅读
目的探讨晚期非小细胞肺癌(NSCLC)患者化疗前后血清癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)和糖类抗原(CA125)的变化。方法选取2013年8月至2015年8月间辽宁省本溪市本钢总医院经病理以及细胞学诊断证实的NSCLC患者42例为研究组,化疗前采用酶联免疫法测定患者血清CEA、CYFRA21-1和CA125表达水平,化疗治疗结束3周后再次测定患者血清中CEA、CYFRA21-1和CA125表达水平变化,并行胸部CT检查,根据结果分为化疗有效者(完全缓解+部分缓解)和无效者(病情稳定+疾病进展)。选取同期来院体检的42例健康者为对照组,均排除肺部疾病,与研究组患者血清中CEA、CYFRA21-1和CA125水平变化进行比较。结果研究组患者化疗前血清CEA、CYFRA21-1和CA125水平分别为(38.78±10.37)ng/ml、(3.51±1.37)ng/ml和(37.22±15.39)U/ml,对照组患者分别为(1.86±0.47)ng/ml、(2.0±0.11)ng/ml和(20.1±15.7)U/ml,两组比较差异有统计学意义(P<0.05)。研究组患者化疗前血清CEA、CYFRA21-1和CA125在化疗有效组和无效组中无显著统计学意义(P<0.05)。化疗后血清CEA、CYFRA21-1和CA125在治疗有效组明显低于化疗前,有显著统计学意义(P<0.05);在无效组化疗后血清CEA、CYFRA21-1和CA125表达水平与化疗前相比差异不大,无统计学意义(P>0.05)。结论对临床NSCLC患者进行血清CEA、CYFRA21-1和CA125检测,可有效评估患者临床疗效及预后,为临床NSCLC化疗疗效提供标准依据。
Objective To investigate the changes of serum carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1) and carbohydrate antigen (CA125) in patients with advanced non-small cell lung cancer (NSCLC) before and after chemotherapy. Methods Forty-two NSCLC patients confirmed by pathology and cytology were selected as the study group from August 2013 to August 2015 in Benxi Iron and Steel General Hospital of Benxi, Liaoning Province. Serum CEA and CYFRA21- 1 and CA125 expression levels were measured again. The serum levels of CEA, CYFRA21-1 and CA125 in the patients were measured again 3 weeks after the end of chemotherapy, and chest CT was performed. According to the results, the patients were divided into chemotherapy-effective (complete remission + partial remission) and ineffective (Stable condition + disease progression). Forty-two healthy subjects from the same period were selected as the control group, and lung diseases were excluded. The changes of serum CEA, CYFRA21-1 and CA125 in the study group were compared. Results The serum levels of CEA, CYFRA21-1 and CA125 in the study group before chemotherapy were (38.78 ± 10.37) ng / ml, (3.51 ± 1.37) ng / ml and (37.22 ± 15.39) U / ml respectively, while those in the control group were 1.86 ± 0.47 ng / ml, (2.0 ± 0.11) ng / ml and (20.1 ± 15.7) U / ml, respectively. There was significant difference between the two groups (P <0.05). The serum levels of CEA, CYFRA21-1 and CA125 in the study group before chemotherapy were not significantly different between the two groups (P <0.05). After chemotherapy, the serum levels of CEA, CYFRA21-1 and CA125 in the treatment group were significantly lower than those in the chemotherapy group (P <0.05), and the levels of CEA, CYFRA21-1 and CA125 in the ineffective group were significantly lower than those in the chemotherapy group No significant difference (P> 0.05). Conclusions Serum CEA, CYFRA21-1 and CA125 levels in patients with NSCLC can be effectively evaluated in clinical efficacy and prognosis of patients with NSCLC, providing a standard basis for clinical NSCLC chemotherapy.